Patient Selection for Rational Development of Novel Anticancer Agents
作者： Grace K. Dy , Alex A. Adjei
DOI: 10.1007/978-1-59745-337-0_26
关键词:
摘要: To understand the challenges a brief overview of issues relevant to drug target and biomarker evaluation will highlight key points involved in process patient selection for rational development novel anticancer agents.
springer.com
sci-hub.st 参考文章(27)
Victor G De Gruttola, Pamela Clax, David L DeMets, Gregory J Downing, Susan S Ellenberg, Lawrence Friedman, Mitchell H Gail, Ross Prentice, Janet Wittes, Scott L Zeger, Considerations in the Evaluation of Surrogate Endpoints in Clinical Trials Controlled Clinical Trials. ,vol. 22, pp. 485- 502 ,(2001) , 10.1016/S0197-2456(01)00153-2
John K. Buolamwini, Alex A. Adjei, Novel anticancer drug protocols Humana Press. ,(2003) , 10.1385/1592593801
Ming-Sound Tsao, Akira Sakurada, Jean-Claude Cutz, Chang-Qi Zhu, Suzanne Kamel-Reid, Jeremy Squire, Ian Lorimer, Tong Zhang, Ni Liu, Manijeh Daneshmand, Paula Marrano, Gilda da Cunha Santos, Alain Lagarde, Frank Richardson, Lesley Seymour, Marlo Whitehead, Keyue Ding, Joseph Pater, Frances A. Shepherd, Erlotinib in lung cancer - molecular and clinical predictors of outcome. The New England Journal of Medicine. ,vol. 353, pp. 133- 144 ,(2005) , 10.1056/NEJMOA050736
Christopher M. Overall, Oded Kleifeld, Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy Nature Reviews Cancer. ,vol. 6, pp. 227- 239 ,(2006) , 10.1038/NRC1821
C Miething, S Feihl, C Mugler, R Grundler, N von Bubnoff, F Lordick, C Peschel, J Duyster, The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib Leukemia. ,vol. 20, pp. 650- 657 ,(2006) , 10.1038/SJ.LEU.2404151
Federico Cappuzzo, Fred R. Hirsch, Elisa Rossi, Stefania Bartolini, Giovanni L. Ceresoli, Lynne Bemis, Jerry Haney, Samir Witta, Kathleen Danenberg, Irene Domenichini, Vienna Ludovini, Elisabetta Magrini, Vanesa Gregorc, Claudio Doglioni, Angelo Sidoni, Maurizio Tonato, Wilbur A. Franklin, Lucio Crino, Paul A. Bunn, Marileila Varella-Garcia, Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer Journal of the National Cancer Institute. ,vol. 97, pp. 643- 655 ,(2005) , 10.1093/JNCI/DJI112
Mark C. Fishman, Jeffery A. Porter, Pharmaceuticals: A New Grammar for Drug Discovery Nature. ,vol. 437, pp. 491- 493 ,(2005) , 10.1038/437491A
Mercedes E Gorre, Mansoor Mohammed, Katharine Ellwood, Nicholas Hsu, Ron Paquette, P Nagesh Rao, Charles L Sawyers, Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification Science. ,vol. 293, pp. 876- 880 ,(2001) , 10.1126/SCIENCE.1062538
Ian E. Smith, Mitch Dowsett, Aromatase Inhibitors in Breast Cancer The New England Journal of Medicine. ,vol. 348, pp. 2431- 2442 ,(2003) , 10.1056/NEJMRA023246
Neil P. Shah, John M. Nicoll, Bhushan Nagar, Mercedes E. Gorre, Ronald L. Paquette, John Kuriyan, Charles L. Sawyers, Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia Cancer Cell. ,vol. 2, pp. 117- 125 ,(2002) , 10.1016/S1535-6108(02)00096-X